JW Pharmaceutical Corporation

KSE 001060.KS

JW Pharmaceutical Corporation Gross Profit for the year ending December 31, 2023: USD 257.80 M

JW Pharmaceutical Corporation Gross Profit is USD 257.80 M for the year ending December 31, 2023, a 13.33% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

JW Pharmaceutical Corporation Gross Profit for the year ending December 31, 2022 was USD 227.48 M, a 15.96% change year over year.
JW Pharmaceutical Corporation Gross Profit for the year ending December 31, 2021 was USD 196.17 M, a 20.37% change year over year.
JW Pharmaceutical Corporation Gross Profit for the year ending December 31, 2020 was USD 162.97 M, a 17.34% change year over year.
JW Pharmaceutical Corporation Gross Profit for the year ending December 31, 2019 was USD 138.88 M, a -21.16% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

KSE: 001060.KS

JW Pharmaceutical Corporation

CEO	Mr. Young-Sub Shin
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	2477, Nambusunhwan-ro
Employees	1,064
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years